title: Propranolol treatment of infantile hemangioma (IH) is not associated with developmental risk or growth impairment at age 4 years.
abstract: BACKGROUND
  Long-term adverse effects of propranolol treatment for infantile hemangioma (IH) in young children have been suggested.
  
  
  OBJECTIVE
  To compare growth and development in children treated with propranolol for IH with nontreated healthy controls.
  
  
  METHODS
  Eighty two (73%) children with IH aged 43 to 51 months treated with propranolol for 6 months or longer, and without other developmental risk factors, were recruited (cases) and matched with 4 twin counterparts and 78 children from a community-based cohort (control subjects). Parents completed the 48-months Ages and Stages Questionnaire (ASQ). Percentages of children with abnormal ASQ results were compared using χ(2) analyses. Mean ASQ scores and growth were compared using Mann-Whitney U tests.
  
  
  RESULTS
  Six (7.3%) cases had abnormal ASQ results, compared with 10 (12.2%) controls (P = .292). Mean ASQ total score (25th-75th percentile) was 52.9 (50.8-57.0) for cases and 51.9 (49.0-56.0) for controls (P = .383). Height and weight of cases and controls were comparable.
  
  
  CONCLUSIONS
  A parent-completed screening instrument was used. The exclusion of children born at gestational age less than 36 weeks and/or children born small for gestational age partly limits generalizability.
  
  
  CONCLUSIONS
  We found no increased developmental risk or growth impairment at age 4 years in patients with IH treated with propranolol.
authors.affiliation: Department of Dermatology, Hecovan Expertise Center for Hemangioma and Vascular Malformations, Nijmegen, The Netherlands. Electronic address: Andre.Moyakine@radboudumc.nl.
authors.forename: Andre Vadimovich
authors.initials: AV
authors.lastname: Moyakine
authors.affiliation: Division of Neonatology, Beatrix Children's Hospital, University Medical Center, University of Groningen, Groningen, The Netherlands.
authors.forename: Jorien Maria
authors.initials: JM
authors.lastname: Kerstjens
authors.affiliation: Department of Medical Psychology, Radboud University Medical Center, Nijmegen, The Netherlands.
authors.forename: Saskia
authors.initials: S
authors.lastname: Spillekom-van Koulil
authors.affiliation: Department of Dermatology, Hecovan Expertise Center for Hemangioma and Vascular Malformations, Nijmegen, The Netherlands.
authors.forename: Catharina Joanna Maria
authors.initials: CJ
authors.lastname: van der Vleuten
mesh_terms: D001827:Body Height; D001835:Body Weight; D016022:Case-Control Studies; D002657:Child Development / Q000187:drug effects*; D002675:Child, Preschool; D005260:Female; D018324:Hemangioma, Capillary / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D019964:Mood Disorders / Q000139:chemically induced; D009386:Neoplastic Syndromes, Hereditary / Q000188:drug therapy*; D011433:Propranolol / Q000009:adverse effects* / Q000627:therapeutic use; D012893:Sleep Wake Disorders / Q000139:chemically induced; D011795:Surveys and Questionnaires; D013997:Time Factors; D014665:Vasodilator Agents / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D014665:Vasodilator Agents; D011433:Propranolol
keywords: Ages and Stages Questionnaire; adverse effects; development; growth; infantile hemangioma; propranolol